Full Press Release Details
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, today highlighted preclinical findings from an abstract accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana. The research, described in